Satish Dayal

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE₂-receptor E-type 4 (EP4), in patients with advanced cancers

David S. Hong, Aparna R. Parikh, Geoffrey I. Shapiro et al. · Journal for ImmunoTherapy of Cancer · 2020 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs

Robert J. Young, Matthew Campbell, Alan D. Borthwick et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1

Thien Duc Tran, Florian Wakenhut, Chris Pickford et al. · ChemMedChem · 2014 · 31 citations

Medicine, Infectious Diseases, Pharmacology +17

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

Duncan Shaw, Ferheen Baig, Ian Bruce et al. · Journal of Medicinal Chemistry · 2016 · 23 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

Ishani Landry, Jagadeesh Aluri, Kenya Nakai et al. · Clinical Pharmacology in Drug Development · 2021 · 21 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9